

3<sup>rd</sup> INTERNATIONAL SYMPOSIUM

**ADVANCED  
OVARIAN CANCER:  
OPTIMAL THERAPY.  
UPDATE**

VALENCIA, SPAIN. MARCH 9<sup>th</sup>, 2001  
PALAU DE LA MÚSICA

## 3<sup>rd</sup> INTERNATIONAL SYMPOSIUM

---

### ADVANCED OVARIAN CANCER: OPTIMAL THERAPY. UPDATE

PROGRAM



#### **DIRECTORS:**

JB VERMORKEN (ANTWERP, BELGIUM),  
A POVEDA (VALENCIA, SPAIN).

#### **SCIENTIFIC COMMITTEE:**

MA BOOKMAN (PHILADELPHIA, USA),  
A CERVANTES (VALENCIA, SPAIN),  
E GARCIA (VALENCIA, SPAIN),  
C MENDIOLA (MADRID, SPAIN),  
A POVEDA (VALENCIA, SPAIN),  
JB TRIMBOS (LEIDEN, THE NETHERLANDS),  
JB VERMORKEN (ANTWERP, BELGIUM).

**08.30h WELCOME**

PROF. A LLOMBART (VALENCIA, SPAIN)

**INTRODUCTION**

V GUILLEM (VALENCIA, SPAIN)

**09.00h 1<sup>st</sup> SESSION:**

**Is early disease really "early"?**

CHAIRMEN: JB TRIMBOS, (LEIDEN, THE NETHERLANDS)

C MENDIOLA (MADRID, SPAIN)

■ **Screening**

IJ JACOBS (LONDON, UNITED KINGDOM)

■ **Molecular approaches**

TC HAMILTON (PHILADELPHIA, USA)

■ **Update Italian Early Ovarian Cancer Studies**

G FAVALLI (BRESCIA, ITALY)

■ **Update Scandinavian Early Ovarian Cancer Studies**

C TROPE (OSLO, NORWAY)

**11.00h COFFEE BREAK**

**11.30h 2<sup>nd</sup> SESSION:**

**New aspects for first-line chemotherapy**

CHAIRMEN: JB VERMORKEN, (ANTWERP, BELGIUM)

A POVEDA (VALENCIA, SPAIN)

**The integration of:**

■ **Paclitaxel (standard and weekly administration) and New Platinum Compounds**

JB VERMORKEN (ANTWERP, BELGIUM)

■ **Docetaxel**

SB KAYE (LONDON, UNITED KINGDOM)

■ **Anthracyclines**

HJ LÜCK (HANNOVER, GERMANY)



■ **Gemcitabine**

SW HANSEN (COPENHAGEN, DENMARK)

■ **Topo-1 inhibitors**

MA BOOKMAN (PHILADELPHIA, USA)

**13.30h LUNCH**

**15.00h 3<sup>rd</sup> SESSION:**

**Miscellaneous Topics**

CHAIRMEN: MA BOOKMAN, (PHILADELPHIA, USA)  
A CERVANTES (VALENCIA, SPAIN)

■ **2<sup>nd</sup> line treatment  
and consolidation therapies**

PF CONTE (PISA, ITALY)

■ **Developmental Chemotherapy:  
GOG Perspective**

MA BOOKMAN (PHILADELPHIA, USA)

■ **New Response criteria in the treatment  
of ovarian cancer:  
RECIST (GCIIG modifications)**

EA EISENHAUER (KINGSTON, CANADA)

■ **I.p. hyperthermia perfusion chemotherapy**

D HAGER (BAD BERGZABERN, GERMANY)

**16.30h COFFEE BREAK**

■ **Present status of High-Dose Chemotherapy**

E PUJADE-LAURINE (PARIS, FRANCE)

■ **Impact of new non-cytotoxics**

EA EISENHAUER (KINGSTON, CANADA)

■ **Intergroup collaborations**

JB VERMORKEN (ANTWERP, BELGIUM)

■ **Remarks and Conclusions**

A POVEDA (VALENCIA, SPAIN)

## GENERAL INFORMATION

---

### VENUE

All sessions will take place at  
**PALAU DE LA MUSICA.**  
Paseo Alameda, 30.  
46023 VALENCIA. Spain

### SCIENTIFIC SECRETARIAT

Dr. **ANDRÉS POVEDA.**  
Fundación IVO.  
C/ Profesor Baguena, 8  
46009 VALENCIA. Spain  
Phone: (34) 96 111 40 00  
Fax: (34) 96 111 43 44  
E-mail: [apoveda@ene.es](mailto:apoveda@ene.es)  
[apoveda@fivo.org](mailto:apoveda@fivo.org)

### ORGANIZING SECRETARIAT

(Registration and Accommodation).  
**ULTRAMAR EXPRESS, Congresos.**

Gran Vía Marqués del Turia, 49 7L3. 46005  
**VALENCIA. SPAIN.**  
Phone (34) 96 352 81 61  
Fax: (34) 96 394 11 58  
E-mail: [hsabal@uex.es](mailto:hsabal@uex.es)

### CREDITS

The symposium has been accredited  
by the European Society of Medical Oncology  
Educational Committee  
for its medical oncology recertification approval  
(ESMO/MORA) program  
with 7 credit/points category 1.

### LANGUAGE

The official language of the  
Symposium is English.  
Simultaneous translation into  
Spanish will be provided.



**ORGANIZED BY:**



SERVICIO DE ONCOLOGÍA MÉDICA,  
FUNDACIÓN INSTITUTO  
VALENCIANO DE ONCOLOGÍA.  
VALENCIA, SPAIN

**UNDER THE AUSPICES OF:**

ESMO, SEOM,  
GEICO, SEGO (sgo).